Image For Activity Cover
PCSS Office-Based Treatment for Opioid Use Disorders - The Half and Half Waiver Course
PCSS Office-Based Treatment for Opioid Use Disorders - The Half and Half Waiver Course - Monday, 11/28/2022

This is PART 1 of the 8-hour waiver eligibility training.

NOTE: This training has a starting time of 8:00 AM Eastern Time.
Please check your time zone for start time and download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

The 1st half of the training is a 4.25-hour live webcast. The 2nd half of the course is a 3.75-hour on-your-own online study. Instructions on how to log on to Part 2 of the course will be provided ONLY to those who complete Part 1 in its entirety. You must be both online viewing and listening to the presentation. Participation in the interactive polling questions is also required in order for the AOAAM to verify attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR CREDIT.

Removal of DATA Waiver (X-Waiver) Requirement
(PCSS will continue to offer waiver trainings during this transition)

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications).

All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so. SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023. For further guidance and updates please continue to check:
https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement

Learning Objectives
  • To understand the federal Drug Abuse Treatment Act (DATA) of 2000 and the subsequent revisions that lists the criteria needed for Office Based Opioid Treatment (OBOT) utilizing buprenorphine for opioid dependence and the new changes/guidelines
  • To distinguish between spontaneous withdrawal and precipitated withdrawal and the appropriate methods of buprenorphine induction
  • To describe and contrast the functions of full mu agonists, partial agonists and antagonists
  • To describe the basic approach used in at least three different types of non-pharmacological treatment of opioid dependence
  • To describe three symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder
  • To list the criteria for establishing the diagnosis of opioid dependence
  • To list at least three situations in which patient information, with patient identity, can be shared under current laws protecting the patient’s confidentiality
  • To understand and minimize buprenorphine misuse and diversion. To be aware of the issues of drug interactions of buprenorphine and pediatric exposures
Credit Statement

This course has been reviewed and is acceptable for 4.25 credits of AOA Category 1A by the AOA CCME. It has also been reviewed and is acceptable for 4.25 Prescribed credit(s) by the American Academy of Family Physicians.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Director

William Morrone, DO, MPH, DABAM, FACOFP & DAAPM, is Medical Director at Recovery Pathways, investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court, Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Dept of Psychiatry. He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.  Dr. Morrone is Director of the Saginaw Chippewa Tribal Court & commissioner on the Governor’s Impaired Driving Commission 2017-2019; he is also Assistant Prof Johns Hopkins School of Nursing.

Summary
Availability: No future session
Cost: FREE
Credit Offered:
4.25 AAFP Credits
4.25 AOA Category 1A Credits
Recommended